To access this element change to forms mode OFF
Grant Award View - GA72363
Developing strategies to overcome venetoclax resistance in chronic...
GA ID:
GA72363
Agency:
Cancer Australia
Approval Date:
24-Feb-2020
Publish Date:
11-Mar-2020
Category:
Cancer
Grant Term:
1-Mar-2020 to 28-Feb-2021
Value (AUD):
$50,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 19/20 Improved cancer control
Grant Program:
2019 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Developing strategies to overcome venetoclax resistance in chronic lymphocytic leukaemia
Purpose:
Australian research has led to the development of venetoclax, a new cancer treatment that targets the key cell survival protein BCL2. This is highly effective for chronic lymphocytic leukaemia patients who have limited treatment options. However, despite achieving deep and durable responses, in most patients the cancer eventually returns while on treatment. The Investigator aims to determine what drives this resistance to venetoclax, and to design new venetoclax combination therapies that may be curative.
GO ID:
GO Title:
2019 PdCCRS for funding commencing in 2020
Internal Reference ID:
1186003
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Melbourne
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
3052
Country:
AUSTRALIA